Company Registration No. 12190419 (England and Wales)
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 DECEMBER 2024
Star House
Star Hill
Rochester
Kent
ME1 1UX
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
CONTENTS
Page
Company information
1
Strategic report
2 - 3
Directors' report
4 - 5
Independent auditor's report
6 - 9
Statement of comprehensive income
10
Statement of financial position
11 - 12
Statement of changes in equity
13
Statement of cash flows
14
Notes to the financial statements
15 - 30
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
COMPANY INFORMATION
- 1 -
Directors
Mr P Fecher
Mr M Fecher
Mr A Fecher
Mr P King
Mr C Davies
Mr D Harries
Secretary
Mr P E King
Company number
12190419
Registered office
Chesterfield Paper Mill
Goytside Road
Chesterfield
S40 2AH
Auditor
TC Group
Star House
Star Hill
Rochester
Kent
ME1 1UX
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
The directors present the strategic report for the year ended 31 December 2024.
During the year under review, the company’s principal trading activity has continued to be the manufacture of paper tissue and towel parent reels. The Northwood AfH Group* operates 3 recycled paper mills with the capacity to service the internal parent reel requirements of the Group’s converting operations.
Fair review of the business
Although there was an upside from lower energy costs and production levels were on par with the previous year. The erosion of the selling price, which was down ~£100/t, and inflationary cost pressures elsewhere in the supply chain meant lower overall profitability in FY24 compared to the previous year. As part of the continued investment in sustainability and energy efficiency, the site invested ~£2½m in the latest screwpress technology for drying the waste product together with new yankee hoods. We should see the full benefits of this capital expenditure in FY25.
Supply of parent reels to associated companies remained at 100% of production volume in the year with overall production being 9% down on budget. Overall tonnes produced was up 2% from FY23 but the lower selling price noted above meant turnover was down £922k compared to FY23. The gross profit percentage was down slightly at 13.8% [13.9% in 2023] and there was an operating profit of £2,118k [£2,055 in 2023].
Principal risks and uncertainties
The company does not operate in a high‑risk environment and the nature of the vertically integrated supply chain that the company works within, along with related companies who are either suppliers or customers, ensures that there is not an over‑reliance on any specific external supplier or customer. The nature of commercial markets means that where sales are made outside the Group, there is a focus on the credit management controls required to minimise the risk of bad debts and to ensure the smooth flow of product. The company continues to comply with all relevant environmental and industry legislation and this is facilitated through continued membership of the CPI. The company has been accredited with the Ecolabel standard meaning that Ecolabel certified products can be manufactured at the company’s related converting plants using base sheet supplied by the business.
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -
Key performance indicators
Mr C Davies
Director
25 September 2025
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 4 -
The directors present their annual report and financial statements for the year ended 31 December 2024.
Results and dividends
The results for the year are set out on page 10.
No ordinary dividends were paid. The directors do not recommend payment of a final dividend.
Directors
The directors who held office during the year and up to the date of signature of the financial statements were as follows:
Mr P Fecher
Mr M Fecher
Mr A Fecher
Mr P King
Mr C Davies
Mr D Harries
Auditor
The auditor, TC Group, is deemed to be reappointed under section 487(2) of the Companies Act 2006.
Statement of directors' responsibilities
The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:
select suitable accounting policies and then apply them consistently;
make judgements and accounting estimates that are reasonable and prudent;
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Statement of disclosure to auditor
So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 5 -
On behalf of the board
Mr C Davies
Director
25 September 2025
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
- 6 -
Opinion
We have audited the financial statements of Northwood Tissue (Chesterfield) Limited (the 'company') for the year ended 31 December 2024 which comprise the statement of comprehensive income, the statement of financial position, the statement of changes in equity, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
- 7 -
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of our audit:
the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.
Responsibilities of directors
As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.
Extent to which the audit was considered capable of detecting irregularities, including fraud
The objectives of our audit, in respect to fraud, are: to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses; and to respond appropriately to fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and its management.
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
- 8 -
Our approach was as follows:
We identified areas of laws and regulations that could reasonably be expected to have a material effect on the financial statements from our general commercial and sector experience, and through discussion with the directors and other management (as required by auditing standards), and discussed with the directors and other management the policies and procedures regarding compliance with laws and regulations;
We considered the legal and regulatory frameworks directly applicable to the financial statements reporting framework (FRS 102 and the Companies Act 2006) and the relevant tax compliance regulations in the UK;
We considered the nature of the industry, the control environment and business performance, including the key drivers for management’s remuneration;
We communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit;
We considered the procedures and controls that the company has established to address risks identified, or that otherwise prevent, deter and detect fraud; and how senior management monitors those programmes and controls.
Based on this understanding we designed our audit procedures to identify non-compliance with such laws and regulations. Where the risk was considered to be higher, we performed audit procedures to address each identified fraud risk. These procedures included: testing manual journals; reviewing the financial statement disclosures and testing to supporting documentation; performing analytical procedures; and enquiring of management, and were designed to provide reasonable assurance that the financial statements were free from fraud or error.
Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. For example, the further removed non-compliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, the less likely the inherently limited procedures required by auditing standards would identify it. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation. We are not responsible for preventing non-compliance and cannot be expected to detect non-compliance with all laws and regulations.
A further description of our responsibilities is available on the FRC’s website at: https://www.frc.org.uk/auditors/audit-assurance/auditor-s-responsibilities-for-the-audit-of-the-fi/description-of-the-auditor%E2%80%99s-responsibilities-for. This description forms part of our auditor’s report.
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
- 9 -
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.
Sally Meah FCCA (Senior Statutory Auditor)
For and on behalf of TC Group
Statutory Auditor
26 September 2025
Star House
Star Hill
Rochester
Kent
ME1 1UX
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2024
- 10 -
2024
2023
Notes
£
£
Turnover
3
23,305,832
24,228,001
Cost of sales
(20,177,702)
(21,098,115)
Gross profit
3,128,130
3,129,886
Administrative expenses
(1,089,692)
(1,074,642)
Operating profit
4
2,038,438
2,055,244
Interest payable and similar expenses
7
(171,819)
(133,861)
Profit before taxation
1,866,619
1,921,383
Tax on profit
8
(272,015)
(479,655)
Profit for the financial year
1,594,604
1,441,728
Other comprehensive income
Revaluation of tangible fixed assets
2,250,549
Tax relating to other comprehensive income
224,755
(715,386)
Total comprehensive income for the year
1,819,359
2,976,891
The income statement has been prepared on the basis that all operations are continuing operations.
The notes on pages 15 to 30 form part of these financial statements.
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT
31 DECEMBER 2024
31 December 2024
- 11 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
9
8,780,987
6,864,608
Current assets
Stocks
10
1,845,728
1,387,132
Debtors
11
12,194,616
11,022,411
Cash at bank and in hand
1,163,398
72,643
15,203,742
12,482,186
Creditors: amounts falling due within one year
12
(12,893,382)
(11,990,367)
Net current assets
2,310,360
491,819
Total assets less current liabilities
11,091,347
7,356,427
Creditors: amounts falling due after more than one year
13
(3,073,612)
(1,205,311)
Provisions for liabilities
Deferred tax liability
16
1,435,423
1,388,163
(1,435,423)
(1,388,163)
Net assets
6,582,312
4,762,953
Capital and reserves
Called up share capital
18
100
100
Non-distributable reserve
2,665,879
2,630,535
Profit and loss reserves
3,916,333
2,132,318
Total equity
6,582,312
4,762,953
The notes on pages 15 to 30 form part of these financial statements.
These financial statements have been prepared in accordance with the provisions relating to medium-sized companies.
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT
31 DECEMBER 2024
31 December 2024
- 12 -
The financial statements were approved by the board of directors and authorised for issue on 25 September 2025 and are signed on its behalf by:
Mr C Davies
Director
Company registration number 12190419 (England and Wales)
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 13 -
Share capital
Non-distributable reserve
Profit and loss reserves
Total
£
£
£
£
Balance at 1 January 2023
100
1,517,229
268,733
1,786,062
Year ended 31 December 2023:
Profit
-
-
1,441,728
1,441,728
Other comprehensive income:
Revaluation of tangible fixed assets
-
2,250,549
-
2,250,549
Tax relating to other comprehensive income
-
(715,386)
(715,386)
Total comprehensive income
-
1,535,163
1,441,728
2,976,891
Other movements
-
(421,857)
421,857
-
Balance at 31 December 2023
100
2,630,535
2,132,318
4,762,953
Year ended 31 December 2024:
Profit
-
-
1,594,604
1,594,604
Other comprehensive income:
Tax relating to other comprehensive income
-
224,755
224,755
Total comprehensive income
-
224,755
1,594,604
1,819,359
Other movements
-
(189,411)
189,411
-
Balance at 31 December 2024
100
2,665,879
3,916,333
6,582,312
The notes on pages 15 to 30 form part of these financial statements.
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 14 -
2024
2023
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from/(absorbed by) operations
22
1,746,774
(1,632,197)
Interest paid
(171,819)
(133,861)
Income taxes paid
(417,486)
Net cash inflow/(outflow) from operating activities
1,157,469
(1,766,058)
Investing activities
Purchase of tangible fixed assets
(2,240,793)
(708,258)
Net cash used in investing activities
(2,240,793)
(708,258)
Financing activities
Proceeds from borrowings
980,679
Repayment of borrowings
(494,680)
Proceeds from hire purchase
1,193,400
Net cash generated from/(used in) financing activities
2,174,079
(494,680)
Net increase/(decrease) in cash and cash equivalents
1,090,755
(2,968,996)
Cash and cash equivalents at beginning of year
72,643
3,041,639
Cash and cash equivalents at end of year
1,163,398
72,643
The notes on pages 15 to 30 form part of these financial statements.
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 15 -
1
Accounting policies
Company information
Northwood Tissue (Chesterfield) Limited is a private company limited by shares incorporated in England and Wales. The registered office is Chesterfield Paper Mill, Goytside Road, Chesterfield, S40 2AH.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention, modified to include the revaluation of plant and machinery. The principal accounting policies adopted are set out below.
1.2
Going concern
Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
1.3
Turnover
Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.
1.4
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Plant and equipment
25 years straight line
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 16 -
1.5
Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
1.6
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.
Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
1.7
Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 17 -
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Other financial assets
Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.
Impairment of financial assets
Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.
Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.
If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.
Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 18 -
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
Other financial liabilities
Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.
Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.
Derecognition of financial liabilities
Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.
1.8
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 19 -
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.9
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
1.10
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.11
Leases
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.
1.12
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 20 -
2
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions in applying the Company's accounting policies to determine the reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates. These estimates and underlying assumptions are reviewed on an
ongoing basis.
Judqements
Critical judgments, apart from those involving estimations that are applied in the preparation of the consolidated financial statements are discussed below;
Leases
Management exercises judgment in determining the classification of leases as finance or operating leases at the inception of the lease. Management considers the likelihood of exercising the break clauses or extension options in determining the lease term. Where the lease term constitutes substantially all the economic life of the asset, or where the present value of minimum lease payments amount to substantially all of the fair value of the property, the lease is classified as a finance lease. All other leases are classified as operating leases.
Estimates
The key assumptions about the future and other key sources of estimation uncertainty at the reporting period end that may have a significant risk of causing material adjustment to the carrying amount of assets and liabilities within the next financial year are discussed below;
Depreciation of property, plant and equipment
Depreciation is provided so as to write down the assets to their residual values over their estimated useful lives. The selection of these residual values and estimated lives requires the exercise of management judgment.
lmpairment of assets
Where there are indicators of impairment, management performs an impairment test. Recoverable amounts for cash-generating units are the higher of fair value less costs of disposal, and value in use.
Stock
Stock is stated at the lower of cost and net realisable value. Cost is determined on a first-in, first-out (FIFO) basis and includes all costs of purchase, conversion, and other costs incurred in bringing the inventories to their present location and condition.
Judgement is required in assessing the net realisable value of stock, which involves estimating future selling prices and costs necessary to make the sale. In particular, management reviews stock for obsolete, slow-moving, or damaged items and makes appropriate provisions where necessary.
Changes in market conditions or customer demand could impact the net realisable value of inventory and result in adjustments to the carrying amount. At the balance sheet date, management considered the stock held and concluded that the provision for obsolete and slow-moving inventory was adequate.
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 21 -
3
Turnover
2024
2023
£
£
Turnover analysed by geographical market
UK
23,305,832
24,228,001
4
Operating profit
2024
2023
Operating profit for the year is stated after charging:
£
£
Exchange losses
2,255
1,853
Depreciation of owned tangible fixed assets
324,414
569,791
Operating lease charges
13,271
7,833
5
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2024
2023
Number
Number
Direct staff
23
23
Indirect staff
27
22
Administration staff
1
1
Directors
6
6
Total
57
52
Their aggregate remuneration comprised:
2024
2023
£
£
Wages and salaries
2,452,293
2,133,702
Social security costs
249,776
213,205
Pension costs
110,794
96,592
2,812,863
2,443,499
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 22 -
6
Auditor's remuneration
2024
2023
Fees payable to the company's auditor and associates:
£
£
For audit services
Audit of the financial statements of the company
19,555
18,665
19,555
18,665
7
Interest payable and similar expenses
2024
2023
£
£
Other finance costs:
Other interest
171,819
133,861
8
Taxation
2024
2023
£
£
Current tax
UK corporation tax on profits for the current period
417,486
Deferred tax
Origination and reversal of timing differences
272,015
62,169
Total tax charge
272,015
479,655
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
8
Taxation
(Continued)
- 23 -
The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:
2024
2023
£
£
Profit before taxation
1,866,619
1,921,383
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2023: 25.00%)
466,655
480,346
Tax effect of expenses that are not deductible in determining taxable profit
81,623
2,734
Tax effect of utilisation of tax losses not previously recognised
(108,303)
Unutilised tax losses carried forward
100,165
Effect of change in corporation tax rate
(26,260)
Permanent capital allowances in excess of depreciation
(648,443)
68,970
Deferred tax adjustment
272,015
62,168
Taxation charge for the year
272,015
479,655
In addition to the amount charged to the income statement, the following amounts relating to tax have been recognised directly in other comprehensive income:
2024
2023
£
£
Deferred tax arising on:
Revaluation of plant and equipment
(224,755)
715,386
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 24 -
9
Tangible fixed assets
Assets under construction
Plant and equipment
Total
£
£
£
Cost or valuation
At 1 January 2024
708,258
6,156,350
6,864,608
Additions
261,793
1,979,000
2,240,793
Transfers
1,350
(1,350)
At 31 December 2024
971,401
8,134,000
9,105,401
Depreciation and impairment
At 1 January 2024
Depreciation charged in the year
324,414
324,414
At 31 December 2024
324,414
324,414
Carrying amount
At 31 December 2024
971,401
7,809,586
8,780,987
At 31 December 2023
708,258
6,156,350
6,864,608
Plant and equipment with a carrying amount of £6,156,350 were revalued at 19th October 2023 by Hilco Valuation Services, independent valuers on the basis of market value. The valuation conforms to International Valuation Standards and was based on technical and financial information pertaining to the subject assets.
If plant and machinery was measured using the cost model, the carrying amounts would have been approximately £4,216,277 (2023 - £2,372,279), being cost £4,636,032 (2023 - £3,071,175) and depreciation £419,755 (£698,896).
10
Stocks
2024
2023
£
£
Raw materials and consumables
433,892
603,365
Finished goods and goods for resale
1,411,836
783,767
1,845,728
1,387,132
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 25 -
11
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
2,219,012
2,325,530
Other debtors
9,410,816
7,960,351
Prepayments and accrued income
564,788
736,530
12,194,616
11,022,411
12
Creditors: amounts falling due within one year
2024
2023
Notes
£
£
Obligations under hire purchase
15
195,627
Other borrowings
14
626,888
516,737
Trade creditors
3,511,057
2,581,013
Corporation tax
417,486
Other taxation and social security
277,382
62,616
Other creditors
726,457
726,536
Accruals and deferred income
7,555,971
7,685,979
12,893,382
11,990,367
13
Creditors: amounts falling due after more than one year
2024
2023
Notes
£
£
Obligations under hire purchase
15
997,773
Other borrowings
14
2,075,839
1,205,311
3,073,612
1,205,311
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 26 -
14
Loans and overdrafts
2024
2023
£
£
Other loans
2,702,727
1,722,048
Payable within one year
626,888
516,737
Payable after one year
2,075,839
1,205,311
M Fecher holds a debenture over all property, plant and machinery of this company dated 19th September 2019, in relation to a loan made to Norpap Property 2019 Limited.
A Chattel Mortgage, dated 27 May 2020 and another dated 10 November 2020, over the company's plant and machinery is held by RBS Invoice Finance Limited as security for the other loan amounting to £2,683,402 (2023 - £1,704,061).
A general debenture dated 27 May 2020 is held by RBS Invoice Finance Limited over the above mentioned loan. The debenture is a fixed and floating charge over property and assets. The loan is repayable in monthly instalments at a fixed rate of interest.
A general debenture dated 10 November 2020 is held by RBS Invoice Finance Limited over the above mentioned loan. The debenture is a fixed and floating charge over property and assets. The loan is repayable in monthly instalments at a fixed rate of interest.
Net obligations under hire purchase contracts are secured on the specific assets financed.
15
Hire purchase obligations
2024
2023
Future minimum lease payments due under finance leases:
£
£
Within one year
293,393
In two to five years
1,173,573
1,466,966
Less: future finance charges
(273,566)
1,193,400
Hire purchase payments represent rentals payable by the company for certain items of plant and machinery. Leases include purchase options at the end of the lease period, and no restrictions are placed on the use of the assets. The average lease term is 5 years. All leases are on a fixed repayment basis and no arrangements have been entered into for contingent rental payments.
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 27 -
16
Deferred taxation
The following are the major deferred tax liabilities and assets recognised by the company and movements thereon:
Liabilities
Liabilities
2024
2023
Balances:
£
£
Accelerated capital allowances
637,260
265,081
Tax losses
(100,164)
-
Revaluations
898,327
1,123,082
1,435,423
1,388,163
2024
Movements in the year:
£
Liability at 1 January 2024
1,388,163
Charge to profit or loss
272,015
Credit to equity
(224,755)
Liability at 31 December 2024
1,435,423
The deferred tax liability set out above is expected to reverse within 12 months and relates to accelerated capital allowances that are expected to mature within the same period.
17
Retirement benefit schemes
2024
2023
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
110,794
96,592
The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.
18
Share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary of £1 each
100
100
100
100
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 28 -
19
Operating lease commitments
Lessee
At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:
2024
2023
£
£
Within one year
356,149
95,000
Between two and five years
774,216
-
1,130,365
95,000
20
Capital commitments
Amounts contracted for but not provided in the financial statements:
2024
2023
£
£
Acquisition of tangible fixed assets
201,564
2,318,043
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 29 -
21
Related party transactions
During the year under review, the following transactions took place with entities over which the entity has significant influence over;
Sales of goods and other recharges of £23,268,188 (2023 - £21,876,280);
The balance due at the year end is £2,216,540 (2023 - £2,325,529) and is included in trade debtors.
Costs of purchases and other recharges of £10,145,391 (2023 - £9,114,671);
The balance due at the year end is £2,242,307 (2023 - £590,201) and is included in trade creditors and accruals and deferred income.
Rent of £278,500 (2023 - £238,500) was paid.
Loans of £7,620,001 (2023 - £2,014,177) were made;
Repayments of £5,394,167 (2023 - £116) were received;
As at 31 December 2024 £8,513,549 (2023 - £6,287,715) was due from the entities.
22
Cash generated from/(absorbed by) operations
2024
2023
£
£
Profit for the year after tax
1,594,604
1,441,728
Adjustments for:
Taxation charged
272,015
479,655
Finance costs
171,819
133,861
Depreciation and impairment of tangible fixed assets
324,414
569,791
Movements in working capital:
(Increase)/decrease in stocks
(458,596)
345,275
Increase in debtors
(1,172,205)
(1,012,005)
Increase/(decrease) in creditors
1,014,723
(3,590,502)
Cash generated from/(absorbed by) operations
1,746,774
(1,632,197)
NORTHWOOD TISSUE (CHESTERFIELD) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 30 -
23
Analysis of changes in net debt
1 January 2024
Cash flows
31 December 2024
£
£
£
Cash at bank and in hand
72,643
1,090,755
1,163,398
Borrowings excluding overdrafts
(1,722,048)
(980,679)
(2,702,727)
Obligations under hire purchase
-
(1,193,400)
(1,193,400)
(1,649,405)
(1,083,324)
(2,732,729)
2024-12-312024-01-01falsefalsefalseCCH SoftwareCCH Accounts Production 2025.200No description of principal activityMr P FecherMr M FecherMr A FecherMr C DaviesMr D HarriesMr D HarriesMr P E King121904192024-01-012024-12-3112190419bus:Director12024-01-012024-12-3112190419bus:Director22024-01-012024-12-3112190419bus:Director32024-01-012024-12-3112190419bus:CompanySecretaryDirector12024-01-012024-12-3112190419bus:Director42024-01-012024-12-3112190419bus:Director52024-01-012024-12-3112190419bus:CompanySecretary12024-01-012024-12-3112190419bus:Director62024-01-012024-12-3112190419bus:RegisteredOffice2024-01-012024-12-31121904192024-12-31121904192023-01-012023-12-3112190419core:RetainedEarningsAccumulatedLosses2023-01-012023-12-3112190419core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3112190419core:RevaluationReserve2024-01-012024-12-3112190419core:RevaluationReserve2023-01-012023-12-3112190419core:RevenueReservesInvestmentFundsOnly2023-01-012023-12-31121904192023-12-3112190419core:ConstructionInProgressAssetsUnderConstruction2024-12-3112190419core:PlantMachinery2024-12-3112190419core:ConstructionInProgressAssetsUnderConstruction2023-12-3112190419core:PlantMachinery2023-12-3112190419core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3112190419core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3112190419core:Non-currentFinancialInstrumentscore:AfterOneYear2024-12-3112190419core:Non-currentFinancialInstrumentscore:AfterOneYear2023-12-3112190419core:CurrentFinancialInstruments2024-12-3112190419core:CurrentFinancialInstruments2023-12-3112190419core:Non-currentFinancialInstruments2024-12-3112190419core:Non-currentFinancialInstruments2023-12-3112190419core:ShareCapital2024-12-3112190419core:ShareCapital2023-12-3112190419core:RevaluationReserve2024-12-3112190419core:RevaluationReserve2023-12-3112190419core:RetainedEarningsAccumulatedLosses2024-12-3112190419core:RetainedEarningsAccumulatedLosses2023-12-3112190419core:ShareCapital2022-12-3112190419core:RevaluationReserve2022-12-3112190419core:RetainedEarningsAccumulatedLosses2022-12-3112190419core:ShareCapitalOrdinaryShareClass12024-12-3112190419core:ShareCapitalOrdinaryShareClass12023-12-31121904192023-12-31121904192022-12-3112190419core:PlantMachinery2024-01-012024-12-311219041912024-01-012024-12-311219041912023-01-012023-12-3112190419core:UKTax2024-01-012024-12-3112190419core:UKTax2023-01-012023-12-3112190419core:ConstructionInProgressAssetsUnderConstruction2023-12-3112190419core:PlantMachinery2023-12-3112190419core:ConstructionInProgressAssetsUnderConstruction2024-01-012024-12-3112190419core:WithinOneYear2024-12-3112190419core:WithinOneYear2023-12-3112190419core:BetweenTwoFiveYears2024-12-3112190419core:BetweenTwoFiveYears2023-12-3112190419bus:OrdinaryShareClass12024-01-012024-12-3112190419bus:OrdinaryShareClass12024-12-3112190419bus:OrdinaryShareClass12023-12-3112190419bus:PrivateLimitedCompanyLtd2024-01-012024-12-3112190419bus:FRS1022024-01-012024-12-3112190419bus:Audited2024-01-012024-12-3112190419bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP